Inhalers are the preferred treatment option for managing t he rising incidence of Chronic respiratory diseases like Asthma and COPD in India. However, it is estimated that nearly 45 percent patients do not adhere to therapy (in terms of filling I refil ling prescriptions or maintaining prescribed medication schedule), which adversely impacts clinical outcomes and patient quality of life. The new device, ADHERO, is designed to improve patient adherence to therapy.
Lupin has collaborated with Aptar Pharma, a leading provider of drug delivery devices, components and services in bringing this first in class device to market.
ADHERO is a bluetooth-enabled, reusable smart device which attaches to the top of a MDI. With built-in sensors, the device t racks the patient's daily medication usage and consumption patterns. Patients can access this information by connecting their ADHERO device to the "MyAdhero" app on their smartphones. The app is also equipped to send reminders, provide contextual health alerts based on factors like Air Quality Index (AQI) at t he patient's current location and enable visual analytics. Physicians too can access patient-related information and medication tracking data through the patient dashboard portal as well as through the app.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
